Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine

Citation
V. De Sanctis et al., Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine, J PED END M, 11, 1998, pp. 827-833
Citations number
11
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
ISSN journal
0334018X → ACNP
Volume
11
Year of publication
1998
Supplement
3
Pages
827 - 833
Database
ISI
SICI code
0334-018X(199812)11:<827:GHSABH>2.0.ZU;2-8
Abstract
An auxological and endocrinological study was performed in 21 thalassaemic patients with growth retardation and skeletal dysplasia secondary to desfer rioxamine. Bone metaphyseal proximal tibial or iliac crest biopsy was perfo rmed in six. patients with severe genu valgum or non-traumatic vertebral co mpression. GH insufficiency/deficiency (GH deficiency: peak after stimulati on test below 6 ng/ml) was found in 72% of our thalassaemic patients with s keletal dysplasia, but in only 41% of patients without skeletal dysplasia, Bone histology showed abnormal chondrocytes, alteration of staining pattern of cartilage, irregular columnar cartilage and lacunae in the cartilaginou s tissue. The behaviour of bone tissue was unpredictable (presence of thick or thin osteoid layer), Bone microfractures were sometimes present. The bo ne microstructure showed scarce mineralization, which was evenly or irregul arly distributed. The bone tissue apatitic phase was quantitatively reduced . The hardness of bone tissue was remarkably lower than that of normal bone in three out of six patients. In conclusion, iron chelation therapy in pat ients with acquired skeletal dysplasia seems to interfere with GH secretion . The early identification of clinical and radiological abnormalities of sk eletal dysplasia is of paramount importance in preventing severe bone destr uction.